In addition, PRMT1 dimethylates the enhancer of zeste homolog 2 (EZH2) at R342 residue, which inhibits the phosphorylation of its T345 and T487 residues, attenuating EZH2 ubiquitylation [61], thereby decreasing the expression of EZH2 target genes and increasing EMT, cell invasion, and BC metastasis [62] (Figure 2). Here, EZH2 is linked to breast cancer.